Eli Lilly benefits from rising cash flow and a strong pipeline, yet elevated pricing versus peers limits near-term gains. See ...

The pharma group did not break down the details of the license to get control of STX-478, described as a next-generation PI3K alpha inhibitor for breast cancer and other advanced solid tumours ...

Eli Lilly will buy Boston biotech Scorpion Therapeutics’ PI3Kα inhibitor for upto $2.5bn in cash, with the latter splitting away to form a new entity with its remaining assets. Lilly’s bid to ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated in a Phase 1/2 clinical trial for breast cancer and other advanced solid tumors. Eli Lilly and Company (NYSE: ...

In January 2025, Eli Lilly announced plans to acquire Scorpion Therapeutics’ experimental cancer therapy, STX-478, for up to $2.5 billion. The kinase inhibitors market is growing significantly and it ...

STX-478 is under clinical development by Scorpion Therapeutics and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase ...

Seagate (STX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase ...

What is the current share price of Strike Energy Limited (STX)? Strike Energy Limited's (STX) current share price is $0.16. This constitutes a price movement of 3.23% when compared to the share price ...